Endeavor BioMedicines’ Post

#fundingalert 💼Company: NextPoint Therapeutics, Inc. 💰Funding: $42.5Million  ⚡Round: Series B 👥Investors: Catalio Capital Management, R. Jacob Vogelstein, MPM BioImpact, Leaps by Bayer, Sixty Degree Capital, Dana-Farber Cancer Institute NextPoint was founded by Ivan Cheung (CEO). The funds will be used to advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional #therapeutic modalities in the pipeline that target the novel HHLA2 tumor antigen. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Their innovative approach integrates #foundational science with a defined #clinical biomarker strategy to deliver a new class of #monotherapies for patients who do not benefit from PD-1/L1 inhibitors. Read more - https://lnkd.in/gx5rqfVC To share your startup story write us on - contact@startuprise.io #nextPoint #funding #startup

🔬💡 Exciting News! 🌟 AltruBio Inc. Raises $225M in Series B Funding! 💰 Originally known as AbGenomics Holdings, the start-up initially focused on developing cancer drugs. But in 2020, it shifted course, swapped out its leadership and rebranded as AltruBio Inc.. The company raised $63 million in funding a year later, followed by a MASSIVE $225M oversubscribed Series B round earlier this week. The round comes amid a surge of industry interest in developers of immune disease drugs and the financing will help the company advance its ulcerative colitis candidate into mid-stage clinical trials. #AltruBio #Biotech #SeriesB #Innovation #UlcerativeColitis #TransformativeTherapies

📣 We are thrilled to see our latest Seed funding activity covered by pharmaphorum. Because we are both a drug development company and a strategic investor, Debiopharm is uniquely positioned to spot and nurture innovative start-ups, getting them ready for the pharmaceutical industry’s needs. Aligned with Debiopharm’s mission, the Innovation Fund invests in technologies that predict, enhance, and speed up the drug development process as well as those that improve the patient experience. Our focus is in oncology, so sometimes we simply call it “Cancer Tech”. 💡If our mission align with yours, don't hesitate to visit our new website to discover how we can support you👉https://lnkd.in/eqU48aby Check out the article below 👇 #seedfunding  #digitalhealth #cancercareinnovation #cancertech #VC #venturecapital #oncology 

Amplia Therapeutics is pleased to announce it has received positive support from existing shareholders of the Company for its fully underwritten, non-renounceable entitlement offer which was announced on 16 April 2024. The Company has raised a total of $4.27 million (before costs). The proceeds from the Entitlement Offer will be used to fund the ongoing Phase 2 ACCENT trial in pancreatic cancer to an Interim Analysis (expected in Q3 2024), as well as undertake production of additional narmafotinib capsules and support a pilot Investigator Initiated Trial in ovarian cancer currently in planning. Amplia’s CEO and Managing Director Dr Chris Burns commented:  “Amplia’s Board and Management are extremely grateful for the ongoing support of our shareholders and advisors, and we welcome new shareholders to the Company. Our successful Entitlement Offer permits the Company to continue to actively progress development of our best-in-class FAK inhibitor narmafotinib, with specific focus on delivering critical interim data in our ongoing Phase 2 ACCENT trial in pancreatic cancer.” Recruitment in the ongoing Phase 2 ACCENT trial is on track with 19 patients recruited to date.    Read the ASX release 👉 https://lnkd.in/euWncWAM     $ATX #Amplia #pancreaticcancer #cancer #biotech #innovation #clinicaltrial #invest 

Recent Funding:  BioAge Labs (Richmond, CA) is rocketing into the new year $170 million richer thanks to a series D. Sofinnova Partners led the financing, which CEO Kristen Fortney says puts the company in a good position to go public in the future. The new funds extend BioAge's runway into late 2026. The financing was fueled by BioAge's entrance into the #obesity space, validated by a collaboration with Eli Lilly and Company. The money will help pay for a phase 2 trial testing BioAge's lead asset, azelaprag, in combination with Lilly's Zepbound in patients with obesity. Latigo Biotherapeutics, Inc. (Thousand Oaks, CA) came out of stealth on with a $135 million Series A. The company is chasing Vertex Pharmaceuticals in the non-opioid #pain race, tackling the same target as VTX-548. The drug was better than placebo at reducing pain intensity in a recently-reported phase 3 trial but failed to beat Vicodin, the standard of care. Westlake Village BioPartners® founded the company in 2020 and has been incubating it since. The company also expects to launch its second molecule into the clinic in the near future, according to interim CEO Desmond Padhi. Firefly Bio (San Francisco) has broken out of stealth, debuting with $94 million and a novel platform to develop degrader-antibody conjugates (DACs), which combine antibody-drug conjugates (#ADCs) with protein degraders to create a new class of therapies to fight #cancer. The company will focus on solid tumor targets that have already been validated in the clinic, specifically targets that have run up against dose-limiting toxicities and could use a more precise approach. Athos Therapeutics Inc is raising a $35 million Series B. The Torrance, CA-based biotech will deploy the money on its #AI-based precision small molecules for #autoimmune diseases and various #cancer indications. About $10 million of the expected haul will go toward the lead asset, an inflammation and mucosal healing-targeted treatment for inflammatory bowel disease, said CEO Dimitrios Iliopoulos. M&A, Deals, Partnerships: Intellia Therapeutics, Inc. will work with ReCode Therapeutics (Menlo Park) to develop #genetic medicines for cystic fibrosis. The collaboration pairs Intellia’s gene editing platform, which is based on #CRISPR technology, with ReCode’s method for delivering genetic medicines to specific organs. “By combining our highly synergistic technologies and capabilities, we are excited about the potential to enable a faster path for next-generation gene editing therapeutics to CF patients,” said CEO Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil. FDA Approvals: The FDA announced one of 2024’s most-anticipated approvals: that of Iovance Biotherapeutics, Inc. (San Carlos) lifileucel for advanced #melanoma. Lifileucel—which will be known commercially as Amtagvi—is the first one-time cell therapy for a solid tumor and the first tumor-infiltrating lymphocytes (TIL) therapy to be approved by the FDA.

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐢𝐬 𝐨𝐧 𝐭𝐡𝐞 𝐮𝐩! 🚀 Two weeks into September and there's been just over $1billion investment secured across 10 companies! For context, in the first two weeks of August we'd seen $520M go out in investment. Congratulations to all that have secured funding this month, with notable mentions being: Mariana Oncology - Next-gen radiopharma innovators securing $175M Series B, which will transition their pipeline into human trials, with a focus on their lead asset MC-339 for small cell lung cancer. Apollo Therapeutics - A huge Series C investment of $226.5M! With over 20 pipeline programs and a scalable R&D platform this is one to watch as they look to further license/acquire more clinical stage programs. Nimbus Therapeutics - A further $210M which brings their total investment over $600M since it's launch 14years ago! The tech-enabled small molecules specialists look to advance several preclinical programs through development with a focus on cancer, autoimmune conditions and metabolic diseases. After a tough year it's great to see more positivity in the market so I'm excited to see what develops as we head into Q4! #biotech #fraserdove #investment #lifesciences

INOVIQ Ltd (ASX:IIQ) is pleased to announce that it has successfully completed an A$7 million placement to institutional and sophisticated investors at A$0.50 per share. Funds raised will be used to advance commercialisation of EXO-NET® research tools and SubB2M diagnostics, progress development of pipeline diagnostics and expedite research of high-value cancer therapeutics, enabling the Company to progress its pipeline and bring new products to market. Over the next 12-months, INOVIQ expects to achieve the following milestones: ◼ Revenue growth from sales of EXO-NET exosome isolation tools (through our Promega partnership and direct sales/services); ◼ Exosome diagnostic biomarker validation for ovarian cancer; ◼ Exosome diagnostic development agreement (collaborator/partner); ◼ Exosome therapeutic in vitro data for breast cancer; and ◼ Commercial partner for SubB2M test for monitoring breast cancer. To read the announcement go to: https://lnkd.in/gRSjY9mw To read the investor presentation go to: https://lnkd.in/gx-RWae7 #INOVIQ #EXONET #Biotech #SmallCaps #Investors #CapitalRaise #Therapeutics #Diagnostics #CancerResearch #LifeSciences

🌱 Latest biotech & pharma fundraising updates 👇 🧠 VectorY closed a $138M Series A co-led by EQT Life Sciences and Forbion. Based in Amsterdam, VectorY focuses on vectorized antibody therapies for neurodegenerative diseases. Proceeds will fund clinical trials for VTx-002, their ALS therapy targeting TDP-43. 💡 RefleXion Medical completed a $105M equity raise led by The Rise Fund. Based in Hayward, CA, RefleXion focuses on expanding radiotherapy for all cancer stages with its SCINTIX technology, which addresses targeting and motion management challenges. The new funds will be used for commercialization and development of new applications for SCINTIX. 🎯 MBrace Therapeutics completed an $85M Series B led by TPG for targeted ADC therapeutics against difficult-to-treat cancers. Based in San Diego, MBrace aims to improve cancer treatments through their proprietary SPARTA approach and lead candidate, MBRC-101. Funds will advance clinical trials, including a Phase 1 study for MBRC-101. 🔍 Cytovale raised an $84M Series C led by Norwest Venture Partners. Based in San Francisco, Cytovale develops early detection technologies for severe diseases. Their lead product, IntelliSep is a rapid sepsis diagnostic test with a blood-to-answer time of under 10 minutes, set to expand nationally. The funds will support IntelliSep's rollout to US hospitals, enhancing sepsis management and treatment. 💪 NMD Pharma A/S secured an $80M Series B led by JEITO. Based in Aarhus, Denmark, NMD is focused on novel treatments for neuromuscular diseases, employing their technology to develop ClC-1 inhibitors like their lead product, NMD670. The funding will advance three Phase 2 studies of NMD670 for myasthenia gravis, spinal muscular atrophy, and Charcot-Marie-Tooth disease, and expand clinical and commercial operations. 🧬 Nouscom AG completed an oversubscribed $72M Series C co-led by Andera Partners, Bpifrance, and M Ventures . Based in Basel, Switzerland, Nouscom focuses on developing neoantigen cancer vaccines, including NOUS-209 and NOUS-PEV. Funds will advance clinical trials, including a Phase 2 study of NOUS-209 for metastatic colorectal cancer. #startups #innovation #finance #seriesa #ipo #entrepreneurship #pharma #biotech #biotechnology #fundraising

Precision oncology company Flindr Therapeutics is pleased to announce the close of its €20million Series A financing, which will be used to advance its first-in-class small molecule inhibitor of RNF31.   Flindr combines world class science and expertise in translational biology, cancer target identification, immune-oncology and small molecule oncology #drugdevelopment. It is led by an expert team of established industry leaders and utilizes the ‘ImmunoGram Drug Discovery Engine’ pioneered in the labs of the highly-regarded The Netherlands Cancer Institute and the Oncode Institute.   The Company will use the funds to advance its lead program, a small molecule inhibitor of #RNF31 to IND, develop an exciting second program, and broaden its pipeline. Flindr is well placed to transform the precision oncology space, with the ability to discover and develop unique #precisiononcology therapeutics, based on novel targets, to eradicate tumors in specific patient populations.   The financing was led by V-Bio Ventures, along with a strong international syndicate comprised of Johnson & Johnson Innovation JJDC Inc, Inc, Qbic Fund | Venture Capital, Flanders Future Tech Fund (PMV), and Curie Capital BV, which were also joined by seed investors Oncode Oncology Bridge Fund (Oncode Institute), Swanbridge Capital, and Brabantse Ontwikkelings Maatschappij (BOM).   For more information, see the full press release via the link in the comments below.   #oncology #biology #financing

🌟 Genmab Expands Its Oncology Portfolio with ProfoundBio Acquisition 🌟 In a significant move for the biotech industry, Genmab has announced its acquisition of ProfoundBio for an impressive $1.8 billion in an all-cash transaction. This strategic acquisition is set to enhance Genmab’s commitment to advancing cancer treatment. Here are the key highlights: 🗯 Enhanced Oncology Portfolio: The acquisition includes ProfoundBio's innovative next-generation antibody-drug conjugates (ADCs), particularly the promising Rina-S, currently in Phase 1/2 trials for ovarian cancer. 📍 Strengthened R&D Capabilities: By integrating ProfoundBio's expertise and technology, Genmab is poised to accelerate its research and development efforts, bringing more groundbreaking therapies to patients in need. 🌎 Global Impact: This acquisition expands Genmab’s reach and capabilities in oncology, aligning perfectly with its mission to improve patient outcomes worldwide. 🎇 Welcoming New Talent: Genmab is excited to welcome the talented team from ProfoundBio into its family, fostering innovation and collaboration in the fight against cancer. This acquisition marks a pivotal moment in Genmab's journey, and the biotech community eagerly anticipates the advancements that will come from this collaboration. ⛰ At Alpine Integrity Group, we make investing accessible through quantitative analysis and tokenomics, providing personalized insights through our various reports and expert guidance. Detailed information can be accessed on our website. Follow us for more updates on relevant financial information! #Genmab #ProfoundBio #Oncology #Biotech #Innovation #CancerTreatment #Healthcare #Teamwork #PatientCare #AlpineIntegrity #AIG #Finance #InvestmentStrategy #Business #CashTransaction